Merida Biosciences
Founded 2022 · 64 employees on LinkedIn · 4 known investors
Merida is a biotherapeutics company developing a new class of drugs designed to selectively and durably eliminate the pathogenic antibodies that drive autoimmune and allergic diseases. Its work spans discovery, drug development, and clinical operations aimed at treating patients with these conditions.
Founders & leadership
Merida Biosciences was founded in 2022 by Pierre Bruhns and Mark Shlomchik.
PB
Pierre BruhnsCo-founder; Director of Research, Pasteur Institute
MS
Mark ShlomchikCo-founder; Professor of Immunology, University of Pittsburgh
MN
Michael NaillinSenior Vice President, Process and Product Development
Investors · 4
Funding
SEC filings, press & company announcementsSource: company announcements and press reports — follow each round's link for the claim.
Founder mafia
2 people who came through Merida Biosciences went on to found or lead other companies.
In the news
Frequently asked questions
- What does Merida Biosciences do?
- Merida is a biotherapeutics company developing a new class of drugs designed to selectively and durably eliminate the pathogenic antibodies that drive autoimmune and allergic diseases. Its work spans discovery, drug development, and clinical operations aimed at treating patients with these conditions.
- Who founded Merida Biosciences?
- Merida Biosciences was founded by Pierre Bruhns, Mark Shlomchik in 2022.
- Who are Merida Biosciences's investors?
- Merida Biosciences's investors include Bain Capital Life Sciences, Third Rock Ventures, Biotechnology Value Fund, GV (Google Ventures).